×

收藏-cq9电子放水规律 网会员访问记录

网页标题:
×

注册cq9电子放水规律 网用户

用 户 名:
联 系 人:
性  别:
密  码:
重复密码:
电子邮箱:
邮箱验证码:
固定电话:
传  真:
手  机:
单位名称:
通信地址:
首选栏目:
我已经认真阅读并同意《cq9电子放水规律 网服务条款》
×

找回密码

  • 1.选择找回方式
  • 2.确认验证信息
  • 3.修改密码
  • 4.修改成功
  • 找回方式:
  • 用 户 名:
  • 手机号码:

 您现在位置:cq9电子放水规律 网-医药产业 >> 研究报告 >> English reports >> English reports >> 浏览医药行业研究报告

Market Report of Monoclonal Antibody Drugs in China (2022)

作者:leigy   来源:本站原创    点击数:0    更新时间:2022-9-20 9:13:54

[关键字]: mAb PD-1 ADC BsAb CTLA-4 DS-8201 BeiGene RemeGen Akeso TopAlliance Innovent Henlius Pembrolizumab "Keytruda"

cq9电子放水规律 网讯:

  Report Title: Market Report of Monoclonal Antibody Drugs in China (2022)

  date: Sep, 2022

  Format:  Adobe PDF

  Price:  $ 9,900

        ¥ 61,800

  Contact: Leo. (Mr. Lei Guangyu) / Ms. Xue zhe

  Tel: 86-10-68012929-2103/2113

  Mobile: 86-13810934380

  E-mail: leigy@zclw8.com


Monoclonal Antibody(mAb) drugs is the largest category of products in the biopharmaceutical industry. This report makes detailed statistics
analysis on the scale growth rate of domestic market, sales volume price trends, competitions, etc. of mAb in various treatment fields and 
different target categories in the past five years.

In recent years, the development marketing of monoclonal antibody drugs have increased rapidly. The number of monoclonal antibody drugs approved in China has increased from 13 in 2017 to 60 in 2022.

image.png

Graph 2 Number of mAB drugs listed in China from 2017 to July 2022

At present, monoclonal antibodies are mainly used in ten therapeutic fields, of which 33 are used for anti-tumor, 15 for rheumatoid other

autoimmune diseases, 3 for fundus maculopathy 2 for cholesterol lowering.

Table 4 Number of mAB drugs listed in China distribution of treatment fields from 2017 to July 2022

image.png

Monoclonal antibody drugs used in the field of anti-tumor therapy can be classified into four categories based on their mechanism of action market characteristics. One category is the traditional drugs targeting tumor related molecules, which can be classified into two sub 
categories: inhibiting the key molecules of tumor survival, activating the innate adaptive immunity against tumors. The other three are the 
most popular categories in recent years: immune checkpoint inhibitors, ADC (Antibody-drug conjugates) Bispecific antibody(BsAb) drugs. 

Table 8 Number of mAB for anti-tumor in China from 2017 to July 2022

image.png

Brentuximab Vedotin for injection is a mAB against CD38. It is the world's first ADC drug developed by Seagen Takeda in 2011. Its brname is “Adcetris”. It is sold by Takeda outside North America.

In 2020, Brentuximab vedotin imported into China for the treatment of lymphoma, which is the most successful commercial ADC drug in the 
field of blood tumor treatment. The specification is 50mg, the price decreased from 22,362 yuan/piece in 2020 to 16,860 yuan in 2021.

However, the negotiation of medical insurance has not been successful.


image.png

Graph 19 Sales volume price comparison of Brentuximab Vedotin for injection from 2020 to 2021

image.png

image.png

image.png

image.png

image.png

image.png

image.png

image.png

image.png

Market Report of Monoclonal Antibody Drugs in China (2022)
注册后,我们会为你提供报告样本并为您提供更全面的咨询服务
您的姓名  称谓: 先生女士
手机号码 
验证号码 
电子邮件 
单位名称 

服务热线

  • 联系项目:86-10-68012929-2103
  • 订购报告:86-10-68012929-2103
  • 邮件订购:leigy@zclw8.com
hhsrh.com hhach.com yysc108.com fzjs888.com dmtyu.com lnfmm.com cxxhjyzx.com jzgkx.com kmgpos.com